OBJECTIVE: To develop an automated and objective method to assess mobility in Parkinson disease (PD) patients in daily-life settings and to investigate whether accelerometer-derived measures discriminate between PD and healthy controls as they walk and simulate activities of daily living (ADL). METHODS: Healthy older adults (17) and patients with PD (22) wore a triaxial accelerometer on their lower back during short walks (validation study) and during a walk around the medical center to simulate daily activities (ADL simulation). The variability (consistency and rhythmicity) of stepping was assessed. The patients completed the walks before and after taking their anti-Parkinsonian medications. Frequency-based acceleration measures included dominant frequency, amplitude (strength of signal frequency), width (frequency dispersion), and slope (a combination reflecting amplitude and width) of the main frequency of the power spectral density in the 0.5- to 3.0-Hz band. A subset of the Unified Parkinson-Disease Rating Scale provided a clinical measure of gait impairment (UPDRS-Gait5). A PD patient and control wore the sensors for 3 days at home. RESULTS: The width was larger, and the amplitude and slope were smaller in the PD patients compared to the controls in the validation study and ADL simulation (P < .02). The width decreased, and the amplitude and slope increased when patients took anti-Parkinsonian medications (P < .007). Significant correlations were observed between acceleration-derived measures and UPDRS-Gait5. The data obtained at home was similar to the clinic data. CONCLUSIONS: Frequency-derived measures are valid and sensitive estimates of stride-to-stride variability that can be used to assess the quality and consistency of walking in patients with PD in real-life settings.
OBJECTIVE: To develop an automated and objective method to assess mobility in Parkinson disease (PD) patients in daily-life settings and to investigate whether accelerometer-derived measures discriminate between PD and healthy controls as they walk and simulate activities of daily living (ADL). METHODS: Healthy older adults (17) and patients with PD (22) wore a triaxial accelerometer on their lower back during short walks (validation study) and during a walk around the medical center to simulate daily activities (ADL simulation). The variability (consistency and rhythmicity) of stepping was assessed. The patients completed the walks before and after taking their anti-Parkinsonian medications. Frequency-based acceleration measures included dominant frequency, amplitude (strength of signal frequency), width (frequency dispersion), and slope (a combination reflecting amplitude and width) of the main frequency of the power spectral density in the 0.5- to 3.0-Hz band. A subset of the Unified Parkinson-Disease Rating Scale provided a clinical measure of gait impairment (UPDRS-Gait5). A PDpatient and control wore the sensors for 3 days at home. RESULTS: The width was larger, and the amplitude and slope were smaller in the PDpatients compared to the controls in the validation study and ADL simulation (P < .02). The width decreased, and the amplitude and slope increased when patients took anti-Parkinsonian medications (P < .007). Significant correlations were observed between acceleration-derived measures and UPDRS-Gait5. The data obtained at home was similar to the clinic data. CONCLUSIONS: Frequency-derived measures are valid and sensitive estimates of stride-to-stride variability that can be used to assess the quality and consistency of walking in patients with PD in real-life settings.
Authors: Vrutangkumar V Shah; James McNames; Martina Mancini; Patricia Carlson-Kuhta; Rebecca I Spain; John G Nutt; Mahmoud El-Gohary; Carolin Curtze; Fay B Horak Journal: J Neurol Date: 2020-01-11 Impact factor: 4.849
Authors: Matin Kheirkhahan; Catrine Tudor-Locke; Robert Axtell; Matthew P Buman; Roger A Fielding; Nancy W Glynn; Jack M Guralnik; Abby C King; Daniel K White; Michael E Miller; Juned Siddique; Peter Brubaker; W Jack Rejeski; Stephen Ranshous; Marco Pahor; Sanjay Ranka; Todd M Manini Journal: Physiol Meas Date: 2016-09-21 Impact factor: 2.833
Authors: Martina Mancini; Mahmoud El-Gohary; Sean Pearson; James McNames; Heather Schlueter; John G Nutt; Laurie A King; Fay B Horak Journal: NeuroRehabilitation Date: 2015 Impact factor: 2.138